Reuters logo
BRIEF-Transgene says U.S. FDA grants IND clearance to Phase 2 trial of TG4010 in combination with Opdivo
September 11, 2017 / 4:11 PM / 9 days ago

BRIEF-Transgene says U.S. FDA grants IND clearance to Phase 2 trial of TG4010 in combination with Opdivo

Sept 11 (Reuters) - Transgene SA:

* Receives FDA IND approval to begin a clinical trial with TG4010 + Nivolumab + Chemotherapy in the first-line treatment of Lung Cancer (NSCLC)

* ‍Phase 2 clinical trial is in collaboration with Bristol-Myers Squibb​

* First patient expected to be enrolled at end of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below